Overview
Mazdutide is a peptide licensed by Innovent Biologics from Eli Lilly. It acts on GLP-1 and glucagon receptors and has been studied mainly in China for weight loss and type 2 diabetes.
Mazdutide is not FDA-approved in the United States. China approved mazdutide injection in 2025.
What is it being studied for?
Research is focused on weight loss and type 2 diabetes, with later work on fatty liver disease.
Mazdutide is based on oxyntomodulin, a naturally occurring hormone. GLP-1 signaling affects appetite, while glucagon signaling affects energy use and liver metabolism.
What has research found?
In a 48-week study of Chinese adults with obesity or overweight, those receiving the higher study dose lost about 14 percent of their starting weight. Those receiving placebo gained about 0.3 percent.
Animal research includes work on diabetes-associated cognitive effects in rodents.
The most commonly reported side effects were digestive.
FDA status and development history
Eli Lilly discovered mazdutide and licensed it to Innovent Biologics for development in China. China approved the injection in 2025. It has no FDA approval.